Oxford BioDynamics's total inventories for the quarter that ended in Sep. 2025 was €0.23 Mil. Oxford BioDynamics's average total inventories from the quarter that ended in Mar. 2025 to the quarter that ended in Sep. 2025 was €0.29 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Oxford BioDynamics's Net-Net Working Capital per share for the quarter that ended in Sep. 2025 was €-0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Oxford BioDynamics's Days Inventory for the
six
months ended in Sep. 2025 was 154.80.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Oxford BioDynamics's Inventory Turnover for the quarter that ended in Sep. 2025 was 1.18.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oxford BioDynamics's Inventory-to-Revenue for the quarter that ended in Sep. 2025 was 0.49.
Oxford BioDynamics (STU:LMQ) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Oxford BioDynamics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oxford BioDynamics's Inventory to Revenue for the quarter that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Oxford BioDynamics Total Inventories Related Terms
Oxford BioDynamics Total Inventories Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Oxford BioDynamics (STU:LMQ) has a Total Inventories of €0.23 Mil as of Sep. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Oxford BioDynamics and its competitors.
Is Oxford BioDynamics' Total Inventories too high?
Oxford BioDynamics' current Total Inventories is €0.23 Mil.
How does Oxford BioDynamics' Total Inventories compare to TMO and DHR?
Oxford BioDynamics' Total Inventories of €0.23 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Oxford BioDynamics and its competitors. Oxford BioDynamics's current Total Inventories is €0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (STU:LMQ) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 95% below its estimated fair value. The current Total Inventories is €0.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Oxford BioDynamics (STU:LMQ), the current Total Inventories is €0.23 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LMQ has been successfully added to your 